Amerikanische Gesellschaft für Hirudotherapie

Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan

Farzali S, Yaraliyeva S, Huseynov F, Manafov A, Saglam N (2025) · Turkiye Parazitolojii Dergisi · n=181

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Khoshnevisan A 202280
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center prospective observational cohort study of hirudotherapy across 11 clinical indications (Herba Medical Center, Baku, Azerbaijan; treatment period 2020-2024)
Sample size (n)
181
Intervention
Disposable medicinal leeches (Hirudo medicinalis) from hygienic Ministry of Ecology and Natural Resources-approved farms; treatment frequency tailored to disease severity (daily, every 3 days, or weekly)
Comparator
No randomized comparator - within-subject pre/post comparison and Pearson correlation between conditions
Primary endpoint
Treatment success rate by clinical condition, calculated based on post-treatment examinations, patient feedback, and physician evaluations
Primary result
Overall success rate 82.68 ± 29.25%; 100% success in osteoarthritis pain (n=50), lipoma (n=8), Raynaud disease (n=3), scleroderma (n=2); high success in thyroiditis (94.44%, n=18), Baker's cyst (80%, n=25), ear diseases (80%, n=10), diabetic foot ulcers (80%, n=5); moderate in eye diseases (75%, n=20); lowest in varicose veins (33.33%, n=30)
Follow-up duration
post-treatment evaluation at session completion

Key Findings

  • Largest single-center Azerbaijani cohort of hirudotherapy across 11 clinical indications (n=181, 2020-2024)
  • Highest reported success rates for osteoarthritis pain (100%, n=50) - consistent with the broader European OA RCT evidence base
  • Lowest success rate for varicose veins (33%) - contrasts with the optimistic Kalender 2014 Turkish RCT
  • Demonstrated operational feasibility of disposable leech protocol with Ministry-approved hygienic sourcing
  • Adds the post-Soviet/Caucasian geography to the international leech therapy evidence base

Limitations

  • Observational cohort with no randomized comparator - severe confounding-by-indication risk
  • Patient-reported and physician-judged 'success' lacks standardized validated outcome measures
  • Single private medical center - selection bias toward CAM-favorable patients
  • Heterogeneous indications with small per-condition samples (n=2-50)
  • No standardized adverse-event reporting protocol described

Clinical Implications

Farzali 2025 is the largest published Azerbaijani hirudotherapy cohort and provides useful real-world utilization data spanning 11 clinical indications. For ASH editorial purposes, the study is cited only as cross-cultural utilization evidence rather than as RCT-level efficacy data. The reported 100% success rate for OA pain is consistent with the European RCT body, while the low varicose-vein success (33%) is a clinically meaningful caution for that indication. The Caucasian geography fills a previously underrepresented region in the hirudotherapy literature.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.